-
Thematic Analysis
Global M&A Deals in H1 2026 - Top Themes by Sector: Strategic Intelligence
If you want to understand the themes that drive an industry, simply look at the list of recent mergers and acquisitions (M&As). This report analyzes the disruptive themes that have driven M&A activity in H1 2026 across all sectors including materials, consumer, energy, financials, healthcare, industrials, technology, media & telecoms. The global M&A market in H1 2026 witnessed deals worth $1.7 trillion, a growth of 47% compared to H1 2025. Â The TMT sector led the M&A deal activity, with deals...
-
Thematic Analysis
Pharmaceutical Drug Development Annual Review 2025
This report investigates the year 2025 in the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern the large-scale changes and how best to pivot to prioritize them within your sector.
-
Thematic Analysis
Modality Intelligence - From Pipeline to Capital: Strategic Intelligence
Antibodies lead pipeline volume and forecast sales, and drive approvals alongside recombinants, but oligonucleotides are scaling fastest off a smaller base. Maturity and innovation stage, not pipeline size, determine where capital lands next. Capital is consolidating around modalities with proven commercial models, and the cost of entry into mAbs, ADCs, siRNA, and BsAbs is rising across M&A, licensing, and VC alike. Within mAbs and recombinants, capital is rotating out of mature mAb mega-deals and into early-stage ADC and recombinant platform...
-
Q2 2026 CRO Activity and Intel Report
This report offers an in-depth analysis of the contract research organization (CRO) industry, categorized by geography, therapeutic area, and phase of development for Q2 2026.
-
Sector Analysis
Diabetic Macular Edema in Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035
This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the diabetic macular edema market through 2033. Drug sales in the DME pharmacotherapy market are expected to grow by a significant margin between 2024 and 2034, with an overall compound annual growth rate (CAGR) of 3.4% over the forecast period. In 2024, GlobalData estimated the total DME market to be valued at $4.42 billion across the 7MM, with the US accounting...
-
Sector Analysis
Type 2 Diabetes (T2D): Epidemiology Forecast to 2035
Type 2 diabetes (T2D), formerly known as non-insulin dependent or adult-onset diabetes, is a chronic condition characterized by a non-autoimmune progressive loss of pancreatic beta cells, which produce insulin (Lu et al., 2024; World Health Organization [WHO], 2024). T2D accounts for over 90% of all diabetes cases, with type 1 and gestational diabetes making up the majority of the remaining cases (Goyal, Singhal and Jialal, 2023). T2D most commonly occurs in persons older than 45 years, however its prevalence in...
-
Thematic Analysis
Pharma M&A Deals H1 2026 - Top Themes: Strategic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in H1 2026 in the pharma Sector.
-
Sector Analysis
Epilepsy (Adults) in Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035
This report covers the 7 major markets and provides an Excel-based forecast model for the epilepsy market through 2035. GlobalData anticipates that the global adult epilepsy market will grow steadily during the forecast period, with 7MM sales expected to increase from $11.4 billion in 2025 to $17.8 billion in 2035, at a compound annual growth rate (CAGR) of 4.5%. In 2025, the US contributed approximately $9.2 billion in drug sales, representing 80.4% of the total adult epilepsy market across the...
-
Product Insights
Oral Cavity (Mouth) Cancer: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Oral Cavity (Mouth) Cancer - Global Clinical Trials Review, 2026" provides an overview of Oral Cavity (Mouth) Cancer Clinical trials scenario. This report provides top line data relating to the clinical trials on Oral Cavity (Mouth) Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Product Insights
Esophageal Cancer: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Esophageal Cancer - Global Clinical Trials Review, 2026" provides an overview of Esophageal Cancer Clinical trials scenario. This report provides top line data relating to the clinical trials on Esophageal Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.